Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here